Potentially malignant disorders (PMD) are recognisable mucosal conditions preceding invasive squamous carcinoma development. Established oral cancer remains a lethal and deforming disease, with a rising incidence. Management techniques for identifiable oral precursor lesions have traditionally been polarised between observational and interventional surgical techniques. By defining salient management goals for treating potentially malignant disease, and examining the evidence supporting the efficacy of treatment intervention, this paper presents the case for interventional laser surgery as a definitive diagnostic and treatment modality.
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| INTRODUCTION
Potentially malignant disorders (PMD) are recognisable oral mucosal lesions, primarily leukoplakia, but also erythroleukoplakia, erythroplakia and proliferative verrucous leukoplakia (PVL), which precede in an unpredictable manner invasive squamous cell carcinoma (SCC) development. 1, 2 Whilst variable malignant transformation rates have been quoted, a systematic review estimated an overall 12% cancer risk over a mean transformation time of 4.3 years. 3 The ensuing morbidity and high mortality consequent upon SCC diagnosis and treatment remain significant in contemporary clinical practice and, whilst the objectives of treating PMD have been poorly defined, most authorities agree that prevention of malignancy is the priority. 4 This is complicated, however, by the widespread, often multifocal nature of disease throughout the upper aerodigestive tract. 1 We have previously defined salient management goals supporting an interventional strategy for PMD management, as outlined in Table 1 , and also published a series of long-term patient cohort studies demonstrating the efficacy of intra-oral CO 2 laser surgical excision, both as an accurate diagnostic tool and a reliable treatment modality particularly for managing "high-risk" PMD. [4] [5] [6] [7] [8] Following initial histopathological diagnosis and risk assessment, mucosal lesions are excised by laser with margins ablated by vapourisation allowing healing by secondary intention. 5 Evidence from a 590 PMD cohort confirmed that interventional surgery provided definitive diagnosis and treatment, facilitated early SCC recognition, identified patients at risk of progressive disease, rationalised follow-up and helped define clinical outcome data. 8 In a recent journal editorial, however, Guneri & Epstein 9 repeat a number of previously raised concerns regarding the use of surgical intervention in PMD management. Whilst these are summarised in Table 2 , of particular concern are the suggestions of "over-treatment," "increased cost of care" and the view that PMD excision "does not show benefit with respect to progression to cancer."
For many years, of course, PMD management was controversially polarised between surgical excision to remove identifiable mucosal disease and conservative medical or observational techniques. 10 Whilst "potential malignancy" is undoubtedly a difficult concept for both patients and clinicians, it intuitively warrants interventional management rather than passive observation. 17, 18 van der Waal, 19 astutely noting that most PMD patients prefer treatment intervention, recommended surgical excision of localised lesions followed by long-term, specialist follow-up, a view supported by many clinicians.
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The aim of this article, therefore, is to review contemporaneous literature regarding PMD treatment and, by addressing each of the stated PMD treatment goals, attempt to clarify the case for interventional surgical management.
| ACCURATE AND DEFINITIVE HISTOPATHOLOGICAL DIAGNOSIS
Characteristic of PMD is the variable presence of epithelial disorganisation and dysmaturation, identified microscopically as dysplasia and graded subjectively for severity. 1,2 Although evidence remains weak, it is generally assumed that more severe dysplasia is at greatest risk of cancer development. and 36%, is seen when incision specimens are compared with their excision counterparts. [22] [23] [24] [25] Incision biopsy, therefore, can only be regarded as a "provisional" diagnosis, with whole lesion excision deemed mandatory for "definitive" PMD diagnosis and grading; the latter is facilitated by CO 2 laser excision. 2, 4, 8, 26 Whilst thermal cytological artefacts at excision margins have been suggested as a limitation of laser biopsy, these do not adversely affect histopathology assessment and reporting by experienced oral pathologists. [5] [6] [7] [8] In addition, it is also recognised that the absence of dysplasia in incision biopsies does not rule out the risk of pre-existing or developing cancer in individual PMD lesions. 25, 27 Multiple lesion disease, particularly widespread and pan-oral presentation, which affects around 25% of PMD patients, is undoubtedly more challenging to manage but the technique of "field mapping" whereby multiple-site incision biopsies are performed to delineate more significant foci of dysplastic disease facilitates pragmatic, targeted intervention to high-risk regions. The likelihood of SCC development is increased in erythroleukoplakia, in severe dysplasia and in lesions arising on the floor of mouth and ventrolateral tongue. ; a figure not dissimilar to the 12% transformation rate quoted in systematic review 3 and an important diagnostic and treatment success. The efficacy of intervention is confirmed in our study cohorts because few patients required post-laser oncology treatment and long-term follow-up revealed excellent clinical outcomes. 7, 8, 25 SCC detection at an early stage enables curative treatment with simple and minor surgical intervention. 4, 32 In contrast, the limitations of PMD observation are highlighted by a 25% malignant transformation rate reported in a UK dysplasia clinic where there was no coordinated treatment protocol and SCC diagnoses only made following clinically evident malignant change. 32 
| EFFECTIVE REMOVAL OF PRE-MALIGNANT TISSUE
As mucosal-only conditions, PMDs do not require the extensive treatment necessary for SCC removal or destruction. It seems selfevident to intervene early and remove dysplastic mucosa whilst "pre-invasive." Surgery can be performed by scalpel, cutting diathermy or photodynamic therapy, but the efficacy of dysplasia excision by CO 2 laser is confirmed in patient cohort studies.
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Dysplasia-free margins or residual foci of mild dysplasia are seen in 75% of treated cases, 7, 30 but with no significant association between dysplasia in resection margins and clinical outcome, almost certainly due to the ability to extend treatment zones by laser ablating oral cavity margins 2-4 mm beyond specimen excision. 4 Whilst minimal intervention has been proposed for less severely dysplastic lesions, treatment of all mucosal pre-malignancy is recommended to reduce risks of recurrence and disease progression consequent upon observing even mildly dysplastic lesions. transformation rates for patients whose lesions were not excised, compared with around 5-6% where lesions were removed. 3, 43 Excluding SCCs excised "unexpectedly," we have noted between 2% and 5% of PMD patients developing same or new-site cancer formation during post-treatment follow-up. [5] [6] [7] [8] Local surgical excision of dysplastic lesions appears to decrease the risk of same-site malignant transformation, but does not eliminate the risk of new-site oral cancer development. 13, 34, 44 The clinical consequence is the realisation that continued patient surveillance, regular clinic monitoring and risk factor profiling remain pertinent for all PMD cases following treatment. 4 
| PATIENT ACCEPTABILITY AND MIN IMAL MOR BIDITY
As CO 2 laser surgery is recommended as the preferred PMD management choice, it is important that it is both acceptable to patients and post-operative morbidity is low. Significant complications following CO 2 laser treatment are rare and, whilst some patients report post-operative pain, submandibular salivary gland swelling following floor of mouth procedures and lingual nerve dysaesthesia after tongue surgery, these are usually transient, self-limiting and rarely require additional treatment. 6, 45 A small number of patients report prolonged complications but these are usually after more extensive surgery, or in those who continue to smoke heavily or consume alcohol after treatment. 45 In general, laser surgery is well tolerated and accepted by patients, aids haemostasis, promotes excellent healing and produces minimal scarring with little functional deficit or patient morbidity. 5 A particular advantage is the ability to repeat excisions or ablations at the same site without compromising oral healing or function. 4, 5 No significant adverse quality of life outcomes for PMD patients has been reported, particularly in contrast to the known physical and psycho-social consequences of SCC treatment. prevention in "at-risk" populations, is cost-effective, but it is not an unreasonable hypothesis. Rather than increasing cost of care, targeted PMD excision is likely to prove less expensive than the alternative of multiple, repeat incision biopsies performed over many years of observational follow-up. 44 There may be additional cost savings in centralising services for PMD patients within specialist oral oncology centres. 
| CONCLUSIONS
Clinical outcomes for oral cancer will only improve by earlier detection of SCC and effective management of precursor lesions with malignant potential. 47 The consequences for an individual patient progressing to SCC are devastating. There seems little to gain from observational strategies, particularly as substantive evidence, summarised in Table 4 , supports the diagnostic and treatment efficacy of intervention as a definitive treatment modality. Interventional laser surgery provides readily available, effective, low morbidity treatment, which is successful in excising PMD mucosal lesions, facilitates early diagnosis of occult SCC and may help reduce overall risk of SCC development.
In the future, PMD patients will require better stratification into "high-risk" and "low-risk" categories, with individually tailored treatment protocols based upon biomolecular and genetic profiling of cancer risk. Whilst awaiting such refinements, and in the absence of meaningful multicentre, prospective randomised trials, the contemporary case for interventional management is presented.
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